Fedratinib demonstrates favorable OS in MDS/MPN overlap syndrome

The results showed a 30% spleen response rate and a 47% symptom response rate among evaluable patients. Overall survival reached around 37 months, which compares favorably to historical controls where survival is typically between one and three years.